Rigel Pharmaceuticals (RIGL) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Rigel Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$294.28M

Latest Revenue (Q)

$69.46M

Main Segment (Y)

Product

Rigel Pharmaceuticals Revenue by Period

Rigel Pharmaceuticals Revenue by Year

Date	Revenue	Change
2025-12-31	$294.28M	64.15%
2024-12-31	$179.28M	53.38%
2023-12-31	$116.88M	-2.79%
2022-12-31	$120.24M	-19.43%
2021-12-31	$149.24M	37.39%
2020-12-31	$108.62M	83.21%
2019-12-31	$59.29M	33.20%
2018-12-31	$44.51M	892.62%
2017-12-31	$4.48M	-78.00%
2016-12-31	$20.38M	-29.46%
2015-12-31	$28.89M	250.24%
2014-12-31	$8.25M	15.38%
2013-12-31	$7.15M	217.78%
2012-12-31	$2.25M	-52.63%
2011-12-31	$4.75M	-96.20%
2010-12-31	$125.00M	16566.67%
2009-12-31	$750.00K	100.00%
2008-12-31	-	-100.00%
2007-12-31	$12.60M	-62.36%
2006-12-31	$33.47M	102.55%
2005-12-31	$16.53M	249.17%
2004-12-31	$4.73M	-57.19%
2003-12-31	$11.05M	-29.98%
2002-12-31	$15.79M	3.17%
2001-12-31	$15.30M	15.77%
2000-12-31	$13.22M	47.13%
1999-12-31	$8.98M	-

Rigel Pharmaceuticals generated $294.28M in revenue during NA 2025, up 64.15% compared to the previous quarter, and up 270.93% compared to the same period a year ago.

Rigel Pharmaceuticals Revenue by Quarter

Date	Revenue	Change
2025-09-30	$69.46M	-31.69%
2025-06-30	$101.69M	90.66%
2025-03-31	$53.33M	-7.40%
2024-12-31	$57.60M	4.14%
2024-09-30	$55.31M	50.12%
2024-06-30	$36.84M	24.74%
2024-03-31	$29.53M	-17.48%
2023-12-31	$35.79M	27.22%
2023-09-30	$28.13M	4.64%
2023-06-30	$26.89M	3.13%
2023-03-31	$26.07M	236.21%
2022-12-31	$7.75M	-65.40%
2022-09-30	$22.41M	-24.85%
2022-06-30	$29.82M	78.18%
2022-03-31	$16.73M	-18.00%
2021-12-31	$20.41M	-5.26%
2021-09-30	$21.54M	-17.98%
2021-06-30	$26.27M	-67.58%
2021-03-31	$81.02M	339.12%
2020-12-31	$18.45M	0.33%
2020-09-30	$18.39M	14.78%
2020-06-30	$16.02M	-71.27%
2020-03-31	$55.76M	262.08%
2019-12-31	$15.40M	-26.16%
2019-09-30	$20.86M	100.41%
2019-06-30	$10.41M	-17.56%
2019-03-31	$12.62M	-66.65%
2018-12-31	$37.86M	678.15%
2018-09-30	$4.87M	172.24%
2018-06-30	$1.79M	100.00%
2018-03-31	-	100.00%
2017-12-31	-	-100.00%
2017-09-30	$900.00K	100.00%
2017-06-30	-	-100.00%
2017-03-31	$3.58M	19.47%
2016-12-31	$3.00M	-20.21%
2016-09-30	$3.76M	-56.25%
2016-06-30	$8.59M	70.89%
2016-03-31	$5.03M	-41.09%
2015-12-31	$8.54M	-34.31%
2015-09-30	$13.00M	150.69%
2015-06-30	$5.18M	138.02%
2015-03-31	$2.18M	-73.60%
2014-12-31	$8.25M	100.00%
2014-09-30	-	100.00%
2014-06-30	-	100.00%
2014-03-31	-	-100.00%
2013-12-31	$5.75M	100.00%
2013-09-30	-	-100.00%
2013-06-30	$1.40M	100.00%
2013-03-31	-	100.00%
2012-12-31	-	100.00%
2012-09-30	-	-100.00%
2012-06-30	$1.50M	100.00%
2012-03-31	$750.00K	100.00%
2011-12-31	-	-100.00%
2011-09-30	$4.36M	1002.53%
2011-06-30	$395.00K	100.00%
2011-03-31	-	100.00%
2010-12-31	-	-100.00%
2010-09-30	$72.28M	46.15%
2010-06-30	$49.46M	1416.62%
2010-03-31	$3.26M	334.80%
2009-12-31	$750.00K	100.00%
2009-09-30	-	100.00%
2009-06-30	-	100.00%
2009-03-31	-	100.00%
2008-12-31	-	100.00%
2008-09-30	-	100.00%
2008-06-30	-	100.00%
2008-03-31	-	-100.00%
2007-12-31	$8.00M	-

Rigel Pharmaceuticals generated $69.46M in revenue during Q3 2025, up -31.69% compared to the previous quarter, and up 188.55% compared to the same period a year ago.

Rigel Pharmaceuticals Revenue Breakdown

Rigel Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Contract revenues from collaborations	$62.03M	$34.38M	$39.02M	$75.73M	-
Government Contract	$265.00K	-	-	-	-
Product	$231.98M	-	-	-	-
Discounts and allowances	$-77.98M	$-65.02M	$-42.76M	$-31.80M	$-18.18M
License	-	$14.00M	-	-	-
Gross product sales	-	$209.92M	$147.06M	$108.52M	$81.19M
Product sales, net	-	$144.90M	$104.29M	$76.72M	$63.01M
Milestone	-	-	$75.00K	-	-
Revenues from collaborations	-	-	$11.49M	-	-
Government contracts	-	-	$1.10M	-	-
Research and development services and others	-	-	-	$6.09M	$3.30M
Government contract	-	-	-	$4.50M	$10.50M
Development milestones	-	-	-	$25.00M	$1.88M
License revenues	-	-	-	$7.93M	$70.55M

Rigel Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 25: Product (107.25%), Contract revenues from collaborations (28.68%), Government Contract (0.12%), and Discounts and allowances (-36.05%).

Quarterly Revenue by Product

Product/Service	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Mar 24	Dec 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
Contract revenues from collaborations	$4.12M	$5.39M	$42.74M	$9.78M	$2.00M	$2.33M	$26.50M	$1.84M	-	-	-	-	-	-	-	-	-	-	-	-
Discounts and allowances	-	$-21.56M	$-20.74M	$-16.64M	-	$-17.39M	$-12.42M	-	$-9.57M	$-9.45M	$-9.72M	$-7.79M	$-7.88M	$-6.42M	$-4.92M	-	-	-	-	-
Product sales, net	-	$64.07M	$58.95M	$43.55M	$79.97M	$38.93M	$26.00M	$56.67M	$23.88M	$23.75M	$22.78M	$19.19M	$18.55M	$16.20M	$17.57M	-	-	-	-	-
Milestone	-	$3.00M	$3.00M	$3.00M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross product sales	-	$85.62M	$79.69M	$60.19M	$115.18M	$56.32M	$38.43M	$80.40M	$33.46M	$33.20M	$32.50M	$26.98M	$26.43M	$22.62M	$22.49M	-	-	-	-	-
License	-	-	-	-	$4.00M	$10.00M	$2.43M	$3.31M	$64.62M	$-1.60M	$2.10M	-	-	-	-	-	-	-	-	-
Revenues from collaborations	-	-	-	-	-	$16.38M	$3.53M	$722.00K	$11.27M	$538.00K	-	-	-	-	-	-	-	-	-	-
Government contract	-	-	-	-	-	-	-	-	$1.00M	$2.00M	$2.50M	$1.00M	-	-	-	-	-	-	-	-
Development milestones	-	-	-	-	-	-	-	-	-	-	$20.00M	-	$5.00M	-	-	-	-	-	-	-
Research and development services and others	-	-	-	-	-	-	-	-	-	-	$1.11M	$722.00K	$3.93M	$330.00K	$1.64M	-	-	-	-	-
License revenues	-	-	-	-	-	-	-	-	-	-	$5.39M	-	$2.34M	$208.00K	$199.00K	-	-	-	-	-
Research And Development Services And Others	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$225.00K	$408.00K	$1.02M	$197.00K	-
Contract Revenues From Collaborations	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$4.53M	$3.71M	$65.64M	$697.00K	$2.10M
Development Milestones	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$1.88M	-	-	-	-
Discounts And Allowances	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-4.53M	$-4.98M	$-3.73M	$-4.67M	$-4.03M
Government Contract	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$1.00M	$5.50M	$3.00M	-	-
Gross Product	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$20.55M	$22.04M	$16.11M	$22.43M	$20.32M
Product	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$16.01M	$17.05M	$12.38M	$17.75M	$16.29M

Rigel Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Dec 25: Contract revenues from collaborations (100.00%).

Rigel Pharmaceuticals Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
RIGL	Rigel Pharmaceuticals	$294.28M	$69.46M
AKBA	Akebia Therapeutics	$236.20M	$58.77M
GOSS	Gossamer Bio	$114.70M	$13.29M
BCYC	Bicycle Therapeutics	$35.27M	$11.73M
PRTA	Prothena	$9.68M	$2.42M
CRVS	Corvus Pharmaceuticals	-	-
VTYX	Ventyx Biosciences	-	-
FDMT	4D Molecular Therapeutics	-	-
KALV	KalVista Pharmaceuticals	-	$13.69M
OLMA	Olema Pharmaceuticals	-	-
OMER	Omeros	-	-

RIGL Revenue FAQ

What is Rigel Pharmaceuticals’s yearly revenue?

Rigel Pharmaceuticals's yearly revenue for 2025 was $294.28M, representing an increase of 64.15% compared to 2024. The company's yearly revenue for 2024 was $179.28M, representing an increase of 53.38% compared to 2023. RIGL's yearly revenue for 2023 was $116.88M, representing a decrease of -2.79% compared to 2022.

What is Rigel Pharmaceuticals’s quarterly revenue?

Rigel Pharmaceuticals's quarterly revenue for Q3 2025 was $69.46M, a -31.69% decrease from the previous quarter (Q2 2025), and a 25.59% increase year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $101.68M, a 90.66% increase from the previous quarter (Q1 2025), and a 176.01% increase year-over-year (Q2 2024). RIGL's quarterly revenue for Q1 2025 was $53.33M, a -7.40% decrease from the previous quarter (Q4 2024), and a 80.58% increase year-over-year (Q1 2024).

What is Rigel Pharmaceuticals’s revenue growth rate?

Rigel Pharmaceuticals's revenue growth rate for the last 3 years (2023-2025) was 151.78%, and for the last 5 years (2021-2025) was 97.19%.

What are Rigel Pharmaceuticals’s revenue streams?

Rigel Pharmaceuticals's revenue streams in c 25 are Contract revenues from collaborations, Government Contract, Product, and Discounts and allowances. Contract revenues from collaborations generated $62.03M in revenue, accounting 28.68% of the company's total revenue, up 80.46% year-over-year. Government Contract generated $265K in revenue, accounting 0.12% of the company's total revenue Product generated $231.98M in revenue, accounting 107.25% of the company's total revenue Discounts and allowances generated $-77.978M in revenue, accounting -36.05% of the company's total revenue, up 19.93% year-over-year.

What is Rigel Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of Rigel Pharmaceuticals was Product. This segment made a revenue of $231.98M, representing 107.25% of the company's total revenue.